Bio-Rad Laboratories, Inc. (BIO.B) company profile
Close on Oct 29, 2026Market cap $10.18BP/E 46.2Yield –
About Bio-Rad Laboratories
Laboratory Analytical Instruments, SIC 3826
Bio-Rad Laboratories, Inc. is a multinational manufacturer and distributor of life science research tools and clinical diagnostics solutions. The company operates through two core segments: Life Science and Clinical Diagnostics. The Life Science division provides instruments, reagents, consumables, and systems to separate, purify, characterize, and quantify biological materials such as cells, proteins, and nucleic acids. Its customers include universities, industrial research facilities, government bodies, pharmaceutical companies, and food testing laboratories. The Clinical Diagnostics segment supplies in vitro diagnostic systems, test kits, informatics software, and quality controls to hospital laboratories, reference laboratories, transfusion centers, and clinics.
The company conducts direct commercial and distribution operations in more than 36 countries outside the United States, complemented by distributors and sales intermediaries worldwide. Its global workforce consists of roughly 7,450 employees distributed across 37 countries, supported by international direct sales and research and development teams. The provided text does not mention the company's headquarters location or founding date.
Summary of the business section of Bio-Rad Laboratories's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Bio-Rad Laboratories, Inc.
- Founded
- 1952
- Headquarters
- Hercules, CA
- Address
- 1000 Alfred Nobel Drive 94547
- Phone
- (510) 724-7000
- Website
- bio-rad.com
- Employees
- 7,450, Dec 31, 2025
- Industry
- Laboratory Analytical Instruments
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Santa Clara, CA
Stock & identifiers
- Ticker
- BIO.B
- Other tickers
- BIO
- Exchange
- NYSE
- IPO date
- Feb 27, 1980
- Shares outstanding
- 27M, Jul 30, 2026
- Public float
- $4.47B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Mar 8, 2002; 3-for-2, Jun 3, 1996; 3-for-2, Jun 11, 1986; 3-for-2, Aug 1, 1985; 2-for-1, Mar 18, 1980
- SEC CIK
- 12208
- CUSIP
- 090572108
- ISIN
- US0905721082
- FIGI
- BBG000BD6WM7
- Share class FIGI
- BBG001S5P622
- LEI
- 549300ZC1GPV35XYDK53
- EIN
- 94-1381833
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Norman D. Schwartz | Chairman & CEO, Director | 7,696,966 |
| Jonathan P. DiVincenzo | President & COO | 2,631 |
| Roop Kalyan Lakkaraju | EVP, Chief Financial Officer | 4,151 |
| Sedat Evran | EVP, Global Supply Chain | 3,880 |
| James Barry | EVP, President, LSG | 2,025 |
| Eva Anette Engelhardt | EVP, President, CDG | 1,828 |
| Courtney C. Enloe | EVP, General Counsel & Sec | 1,652 |
| Rajat Mehta | EVP, GBL Commercial Operations | 1,232 |
| Colleen Corey | EVP, Global Human Resources | 19,550 |
| Michael Crowley | EVP, GBL Commercial Operations | 8,171 |
| Schwartz Allison | Director | 1,768 |
| Melinda Litherland Pei | Director | 715 |
| Jeffrey L. Edwards | Director | 715 |
| Greg K. Hinckley | Director | 1,215 |
| Arnold A. Pinkston | Director | 715 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $8.00M | $7.26M | $2.99M | $52 | $105 |
| FY2024 | $8.29M | $8.62M | $3.14M | $56 | $100 |
| FY2023 | $7.46M | $1.02M | $2.54M | $55 | $104 |
| FY2022 | $7.53M | -$5.58M | $2.61M | $72 | $107 |
| FY2021 | $8.70M | $20.35M | $3.19M | $130 | $139 |
| FY2020 | $7.99M | $21.28M | $2.83M | $158 | $133 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Norman Schwartz Chief Executive Officer and Chairman | $1.09M | $4.86M | $1.46M | $562.09K | $28.33K | $8.00M | -4% |
| Roop K. Lakkaraju Executive Vice President, Chief Financial Officer | $629.10K | $1.62M | $387.36K | $334.21K | $21.11K | $2.99M | -21% |
| Jonathan P. DiVincenzo President and Chief Operating Officer | $673.21K | $2.02M | $484.12K | $476.70K | $23.04K | $3.68M | -15% |
| Rajat Mehta Executive Vice President, Global Commercial Operations | $220.10K | $2.16M | – | $270.11K | $31.13K | $2.68M | – |
| James Barry Executive Vice President, President, Life Science Group | $536.75K | $1.21M | $290.49K | $266.08K | $303.69K | $2.61M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“At December 31, 2025, we had approximately 7,450 employees, the overwhelming majority of which are full-time employees.”
Corporate history
Events identified from SEC filings